ALK and non-small cell lung carcinoma: In the final OS analysis from the CHOICE-01 trial, incorporating toripalimab into standard first-line chemotherapy dramatically enhanced OS outcomes of NSCLC patients who do not possess EGFR/ALK driver mutations, aligning with the results from the interim OS analysis.